Vaccinating Veterans for COVID-19 at the U.S. Department of Veterans Affairs.
Journal
American journal of preventive medicine
ISSN: 1873-2607
Titre abrégé: Am J Prev Med
Pays: Netherlands
ID NLM: 8704773
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
31
08
2021
revised:
18
11
2021
accepted:
09
12
2021
pubmed:
22
2
2022
medline:
25
5
2022
entrez:
21
2
2022
Statut:
ppublish
Résumé
With the COVID-19 (most recent) Omicron variant surge across the U.S., more research is needed to better understand how vaccination and booster uptake can be increased. COVID-19 vaccinations have proven to help decrease the likelihood of becoming seriously ill, getting hospitalized, or dying. Studies examining patient characteristics of individuals who received COVID-19 vaccinations are limited. This study examines the patient characteristics of veterans who were vaccinated during the first 8 months (December 2020-July 2021) of the vaccination rollout at the U.S. Department of Veterans Affairs. Using the U.S. Department of Veterans Affairs administrative and clinical data, bivariate and multivariate analyses were conducted to determine sociodemographic and health factors associated with the likelihood of receiving COVID-19 vaccination at the U.S. Department of Veterans Affairs. The analytic sample included 5,914,741 U.S. Department of Veterans Affairs users (49.7% vaccinated). Among the U.S. Department of Veterans Affairs medical facilities nationwide, COVID-19 vaccination rates (≥1 dose) varied from 33.9% to 73.7%. Veterans who were non-Hispanic American Indian/Alaskan natives, younger, living in rural areas, male, and unmarried; had U.S. Department of Veterans Affairs health insurance only; had fewer chronic conditions; did not receive the seasonal influenza vaccine; and were not living in community living centers or nursing homes were less likely to get vaccinated. Understanding which groups of veterans are less likely to be vaccinated allows the U.S. Department of Veterans Affairs to develop targeted interventions to improve uptake in these groups. These results can also guide non-U.S. Department of Veterans Affairs organizations to create evidence-based educational outreach programs that reduce vaccine hesitancy among veterans who do not use U.S. Department of Veterans Affairs.
Identifiants
pubmed: 35184947
pii: S0749-3797(22)00051-4
doi: 10.1016/j.amepre.2021.12.016
pmc: PMC8806154
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e317-e324Informations de copyright
Published by Elsevier Inc.
Références
JAMA Netw Open. 2021 Nov 1;4(11):e2132548
pubmed: 34730819
JAMA. 2016 Feb 9;315(6):560-1
pubmed: 26864409
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Community Health. 2021 Dec;46(6):1244-1251
pubmed: 33877534
J Community Health. 2021 Apr;46(2):270-277
pubmed: 33389421
JAMA Netw Open. 2020 Oct 1;3(10):e2025594
pubmed: 33079199
Vaccine X. 2021 Dec;9:100116
pubmed: 34580652
MMWR Morb Mortal Wkly Rep. 2021 Feb 05;70(5):174-177
pubmed: 33539333
Arch Intern Med. 2000 Nov 27;160(21):3252-7
pubmed: 11088086